Vor to Participate in Two Upcoming Investor Conferences
January 04, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the JMP Securities Hematology and Oncology Summit
November 29, 2021 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
November 19, 2021 16:01 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
November 10, 2021 16:10 ET
|
Vor Biopharma
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML ...
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
November 09, 2021 08:30 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel...
Vor to Participate in Two Upcoming Investor Conferences
November 08, 2021 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief...
Vor to Present New Platform and Preclinical Data at ASH
November 04, 2021 09:15 ET
|
Vor Biopharma
Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted TherapiesMultiplex Engineering of Human CD34+ HSPCs Enables...
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
October 19, 2021 07:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel...
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
October 12, 2021 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as...
VOR33 Granted U.S. FDA Fast Track Designation for AML
September 09, 2021 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration...